Related Experiment Video
Updated: Aug 21, 2026

Quantitative 3D In Silico Modeling (q3DISM) of Cerebral Amyloid-beta Phagocytosis in Rodent Models of Alzheimer's Disease
Published on: December 26, 2016
Neuroinflammatory and molecular pathways in Alzheimer's disease: mechanistic crosstalk and emerging therapeutic
Abhay Thakur1, Rohit Sharma2, Sneha Kumari3
1Department of Pharmacy, Career Point University, Hamirpur, H.P, 176041, India.
Abstract:
Alzheimer's disease (AD) is a multifactorial and progressive neurodegenerative condition characterized by the interaction of various molecular, cellular and systemic mechanisms that culminate in synaptic dysfunction, neuronal loss and memory decline. Therapeutic success remains limited despite decades of research, and accumulating evidence suggests that an exclusive focus on single-pathology mechanisms may have contributed to the limited efficacy of many therapeutic strategies. The interplay of pathogenic mechanisms seems to contribute to the disorder in a dynamic and continuous manner, much like the growing evidence supporting a network-based model. This review engages with 30 major pathogenic pathways contributing to AD, including amyloid-β and tau pathology, neuroinflammation, oxidative stress and mitochondrial dysfunction, synaptic and neurotransmitter dysfunction, metabolic and vascular dysfunction, calcium signaling, proteostasis ,gut-brain axis and hormone-related pathways. The study also presents emerging mechanisms such as metal ion dishonesties, prion-like propagation and Wnt/β-catenin Signaling. Particular emphasis is placed on neuroinflammatory and immunometabolism pathways, which mediate the clearance of amyloid, propagation of tau, maintenance of synaptic integrity, and regulation of neurovascular function. In addition, the review examines therapeutic strategies targeting these pathways, including monoclonal antibodies, inflammasome inhibitors, metabolic modulators, and emerging gene- and RNA-based therapies. Multi-target and precision medicine approaches represent promising strategies for potential disease modification, although their clinical efficacy remains under investigation.Overall, this review makes a case for integrative, pathway-based therapeutic models, and multiple approaches may facilitate for drug development, biomarker identification and patient management in Alzheimer's disease.
Related Concept Videos
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
Alzheimer Disease ll: Pathophysiology
Alzheimer's Disease: Treatment
Alzheimer Disease l: Introduction
Parkinson Disease ll: Pathophysiology
Dementia l: Introduction